Frontier IP (FIPP) announced on Thursday it has acquired a 10% stake in Amprologix Limited, a spin-out from the University of Plymouth. The company has been established to introduce new antibiotics to tackle antimicrobial resistance, a major threat to human health globally.
First product cream containing epidermicin – combat infections caused by antibiotic resistant bacteria. It rapidly kills harmful bacteria even if they are resistant to other antibiotics and even at very low doses.
No new classes of antibiotics have been introduced into clinical use for the past 30 years. The company aims to meet growing need for new antibiotics as microbes become increasingly drug resistant
Working with IBM, the National Physical Laboratory and Ingenza, the company focus is using Artificial Intelligence to improve antibiotic properties. The partnership with biotechnology and synthetic biology company Ingenza will allow the company to manufacture antibiotics at scale.
The World Health Organisation warned in February this year that "antibiotic resistance is one of the biggest threats to global health, food security, and development today".
Frontier IP (FIPP) was up over 10p per share by the end of the week following the announcement.
Follow news & updates about Frontier IP (FIPP) here: